Lumenis Ltd has received marketing clearance from the US Food and Drug Administration for its Novus TTx, 810 Nanometer Infrared Diode Photocoagulator.

"Novus TTx combines the power of an 810 nanometer infrared laser with Lumenis' exclusive and highly-adaptable user interface, giving ophthalmologists an advanced device to treat even the most complicated retinal conditions, such as choroidal neovascularization, age-related macular degeneration, retinopathy of prematurity and intraocular tumors" stated Avner Raz, President and Chief Executive Officer. "With the addition of Novus TTx to our existing photocoagulator, SLT, photoactivator and photodisruptor platforms, Lumenis offers a minimally-invasive option for nearly every major eye disease."

The only ophthalmic 810 nm diode photocoagulator with four energy delivery modes, Novus TTx allows ophthalmic surgeons to precisely control the amount of energy used during each customized laser treatment. The portability and high-energy delivery potential of the TTx 810 nm photocoagulator makes it suitable for both the outpatient clinic and operating room.